Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting antithrombin marker. Our state-of-the-art technologies ensure that our clients receive high-quality, stable, flexible, and cost-effective products and services.
Introduction of Antithrombin
Antithrombin (AT) is a 58-kDa plasma glycoprotein synthesized in the liver and belongs to the family of serine protease inhibitors (serpins). It contains three disulfide bonds and a total of four possible glycosylation sites. As a predominant naturally occurring inhibitor of coagulation, AT inactivates several enzymes of the coagulation system and targets activated factor II (factor IIa; thrombin) and factor Xa. Studies have suggested that AT is implicated in angiogenesis and its role of antiangiogenic and antitumor have provided evidence that the clotting and fibrinolytic pathways are directly related to the regulation of angiogenesis. Furthermore, AT also plays an important role in regulating normal blood coagulation and antithrombin deficiency generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism.
Fig.1 Anticoagulant mechanisms of antithrombin, which mainly inhibits factor IIa and factor Xa, but also factors VIIa, IXa, XIa, and XIIa (Martinelli., 2014)
Antithrombin Marker of Sepsis
Activation of inflammation and coagulation is important in the pathogenesis of sepsis. Natural anticoagulant pathways have a central position at the crossroads of coagulation and inflammation pathways and the restoration of defective anticoagulant pathways in patients with sepsis has, therefore, received considerable attention. It has been reported that plasma levels of antithrombin are (very) low in patients with sepsis and are independent predictors of the clinical outcome. Moreover, a substantial drop in the level of circulating antithrombin has been demonstrated to be a very early phenomenon in sepsis which lends support to the idea that this protease inhibitor is involved in the pathogenesis of the disease. In this case, the plasma level of AT can be used as a potential and specific marker for the diagnosis of sepsis.
Fig.2 Pathogenesis of disseminated intravascular coagulation in sepsis (Allen., 2015)
IVD Antibody Development Services for Antithrombin Marker
In recent years, IVD technologies are undergoing rapid development. IVD antibodies have been extensively used for the diagnosis of numerous diseases, conditions, or infections. Numerous candidate biomarkers were introduced as specific biomarkers for discrimination of indolent and advanced disease. As a pioneer company in the IVD market, Creative Biolabs has provided a variety of IVD antibody development services for our global customers in the most high-quality and cost-effective way.
If you are interested in the services we provide, please feel free to contact us and get a quote.
References
For Research Use Only.
